Bausch + Lomb Corporation announced the creation of Orphia, a new AI-powered digital health platform designed to reduce the operational burden that stands between physicians and their patients. The platform is brand agnostic and built to serve all eye care providers, regardless of the products, devices, or treatments they use. This initiative aims to allow physicians to spend less time managing disconnected tools and more time delivering care.

Orphia will operate under Digital Health Services, a newly created platform at Bausch + Lomb. The first application of the platform focuses on pre-surgery cataract education, helping patients understand their condition and treatment options before meeting with their surgeon. The goal is to ensure patients arrive informed, allowing physicians to focus on achieving the best possible vision outcomes.

To assist with the development of conversational patient engagement capability, Bausch + Lomb has engaged Hippocratic AI. This partnership leverages Hippocratic AI's proprietary Large Language Model (LLM), built on more than 200 million real patient interactions and validated by more than 7500 U.S.-licensed clinicians.

Strategic Integration and Expansion

Orphia is designed to integrate with the systems that practices already use, complementing existing workflows and creating actionable insights for clinical teams. Over time, Bausch + Lomb plans to expand the platform’s capabilities to support the full patient journey, from care coordination to practice workflow.

Leadership and Vision

The Orphia digital health platform will be led by Manisha Narasimhan, PhD, President of Digital Health Services at Bausch + Lomb. Narasimhan brings nearly two decades of experience spanning biotechnology, strategy, corporate development, and digital transformation.

Brent Saunders, Chairman and CEO of Bausch + Lomb, emphasized that the platform was created to serve every eye care provider. "Orphia was created to serve every eye care provider, no matter what they prescribe or what product they use," Saunders said.

Citigroup analyst Joanne Wuensch has maintained a Buy rating on Bausch & Lomb while raising the price target to C$21 from C$19. The adjustment reflects a revised valuation outlook for the company's stock.

Rating and Price Target Details

The research note updates the investment stance on Bausch & Lomb, retaining the Buy recommendation. The price target increase signifies an improvement in the expected share price performance.

Bausch & Lomb is listed on the TSX under the ticker symbol BLCO.